Genetics or Microenvironment: What Drives CLL Progression?
MILAN — Is chronic lymphocytic leukemia (CLL) progression primarily driven by genetic mutations or by external cues from the tumor microenvironment? Despite major strides in targeted therapies, CLL remains incurable, prompting renewed scrutiny of whether intrinsic genetic alterations or extrinsic cellular forces hold the key to more effective, lasting treatment.
This central question took the spotlight at the 2025 European Hematology Association (EHA) Annual Congress, sparking a lively debate among leading CLL researchers.
Most therapies have targeted intrinsic molecular features of leukemic cells, such as BCL2 and BTK. But the lack of robust responses to immunotherapy suggests that external factors such as the tumor microenvironment may also play a role.
'The debate dates back to at least 1999,' said session chair Silvia Deaglio, MD, PhD, director of the Immunogenetics and Transplant Biology Service, City of Health and Science of Turin, Italy in an interview with Medscape Medical News . 'That year, two landmark papers showed that mutations in IGHV [immunoglobulin heavy chain variable region] genes were a favorable prognostic marker, supporting a genetic model. But those same studies also identified an unfavorable prognostic marker in a molecule linked to how CLL cells interact with their environment, suggesting a role for the microenvironment as well.'
Genetic Drivers Take Center Stage
Eugen Tausch, MD, PhD, researcher at the University of Ulm, Germany, argued in favor of genetics as the primary driver. 'All CLLs have at least one genetic driver, and IGHV mutation status is a fundamental and stable biomarker,' he said.
This mutation status affects multiple cellular mechanisms, including immune evasion, anti-apoptotic signaling, and B-cell receptor function. It also modulates how cells respond to cues from their environment, reinforcing the need to consider IGHV when studying microenvironmental influences.
But IGHV is just one piece of the puzzle, Tausch added. More than 200 genetic drivers have been identified in CLL. Roughly 90% of cases harbor at least one gene mutation or chromosomal aberration that affects DNA repair, cell cycle regulation, metabolism, RNA processing, and intracellular signaling. 'These alterations have clear clinical implications,' he said. 'Resistance to BTK and BCL2 inhibitors often arises through mutations at the drug-binding site, establishing a direct link between genetics and therapy failure.'
Understanding and tracking clonal genetic evolution is thus key to risk stratification, treatment planning, and anticipating disease trajectory, he concluded.
The Microenvironment's Role in Early Disease
Although CLL has long been seen as a genetically driven malignancy, new data suggest a more nuanced picture in which the tumor microenvironment influences early clonal dynamics.
'We know mutations drive disease progression, especially under therapeutic pressure, but the triggers of these mutations are less clear,' said John Gribben, MD, DSc, Hamilton Fairley Professor of Medical Oncology at Barts Cancer Institute, Queen Mary University of London, UK, who argued in favor of the microenvironment. Accumulation of mutations with age, oxidative stress, antigenic stimulation, and rare inherited factors have all been proposed, but these likely act in concert with tumor microenvironment signals to promote early clonal expansion, he explained.
In lymph nodes and bone marrow, CLL cells interact with a milieu of stromal and nurse-like cells, dysfunctional T cells, and dendritic cells, along with a variety of cytokines and chemokines. Recent studies have shown that early clonal evolution primarily occurs in lymph nodes and is associated with a suppressed T-cell inflammatory response. A small subpopulation of lymph node-activated CLL cells engages with the microenvironment to drive disease progression and possibly influence mutation patterns.
Moreover, therapies that disrupt microenvironmental interactions have shown efficacy by blocking B-cell receptor signaling and impairing chemokine-mediated trafficking.
Even while advocating for the microenvironment's role, Gribben proposed a hybrid model. 'Genetic lesions set the stage, but microenvironmental forces shape their emergence and survival. Early on, extrinsic factors dominate. Later, clonal evolution and genetic resistance take over.'
A New Paradigm of Coexistence
Both speakers emphasized the need to move beyond binary models of CLL progression. 'The data support a dynamic interplay,' Deaglio told Medscape Medical News . 'The long-term coexistence between leukemic cells and their environment in CLL alters both cell behavior and immune function.' She noted that the T-cell compartment becomes tolerogenic, showing expansion of regulatory T cells and memory effector cells, among other markers.
The debate also touched on the progression from monoclonal B-cell lymphocytosis to CLL and on Richter transformation, reinforcing the need for an integrated understanding of intrinsic and extrinsic disease drivers.
Deaglio underlined that researchers are now exploring whether treatment-resistant patients could benefit from new drugs or combinations and whether therapy could eventually be administered for fixed durations rather than continuously until progression.
'Progression is genetically driven,' said Deaglio. 'But single-cell sequencing shows that some leukemic cells carry the features that enable future expansion a long time before the disease is diagnosed. Why some clones grow while others do not may depend on the environment they find themselves in.'
Gribben concluded, 'To treat CLL effectively, and maybe reach a cure, we'll need to combine immune-based approaches with current targeted therapies.'
Deaglio reported no relevant financial relationships. Tausch reported industry affiliations with AbbVie, BeiGene, Lilly, AstraZeneca, Roche, and Janssen-Cilag. Gribben reported research funding from AstraZeneca, BMS/Celgene, and Janssen; clinical trials with AbbVie, Celgene, Epizyme, Gilead, Genmab, Janssen, Merck, MorphoSys, Pharmacyclics, Regeneron, Roche/Genentech, and Takeda; consultancy for AbbVie, Amgen, AstraZeneca, BeiGene, BSM/Celgene, Janssen, Kite Gilead, and Takeda; and honoraria from AbbVie, AstraZeneca, BeiGene, BSM/Celgene, Janssen, Kite Gilead, and Novartis.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Gaia, Europe's Galactic Cartographer, Is Gone But Not Forgotten
This observatory has probably been the most transformative astronomy project of the 21st century, but there's a good chance you've never heard of it. Just last week, for instance, the Hayden Planetarium at the American Museum of Natural History (AMNH) in New York City debuted a new 'space show' called Encounters in the Milky Way—and this often overlooked spacecraft is its scientific superstar. But you're more likely to know about actor Pedro Pascal's narration in the show than you are to be familiar with the single space mission that serves as the presentation's backbone. The observatory is called Gaia. And, like so many good things, you wouldn't really miss it until it's gone—and now it is. Launched in 2013 by the European Space Agency (ESA), it ceased operations this past March, when it used what little fuel it had left to steer into a graveyard orbit around the sun. From its station in a quiescent region of deep space more than 1.6 million kilometers from Earth, Gaia's mission was, in essence, quite simple: it was designed to give us a better sense of where we are—a celestial 'reference frame' on overlapping interplanetary, interstellar and intergalactic scales. To do that, it used twin sky-sweeping telescopes and three instruments, including a billion-pixel camera, to painstakingly measure the distances, positions, motions, and more of about two billion celestial objects, most of them stars in our own galaxy. It made some three trillion observations in all, producing (among many other things) the largest, most precise three-dimensional map of the Milky Way ever made. [Sign up for Today in Science, a free daily newsletter] 'Gaia was our best galactic cartographer, and I sometimes say that Encounters in the Milky Way is my love letter to it,' says Jackie Faherty, a senior research scientist at the AMNH, who curated the new space show and regularly works with Gaia data. 'It turns out you can learn a lot by determining where and how far off the stars are from you—and especially by how they are moving.... Gaia's creation of this map is something we all should celebrate because it's just as iconic and useful as the maps of Earth we all see in school or pull up on Google. Looking at it, you can find and explore all sorts of different things you want to know.' From Gaia's map, more than 13,000 peer-reviewed studies have already emerged, and many have concerned the fundamental structure and deep history of the Milky Way. Thanks to Gaia, scientists now can better gauge the amount of dark matter within our galaxy and have been able to track the Milky Way's growth and evolution across eons via relic streams of stars strewn from ancient mergers with other, smaller galaxies. 'Stars retain memories of their origins in their ages, motions and chemical compositions—all of which Gaia measured,' says Amina Helmi, an astronomer at the Kapteyn Astronomical Institute in the Netherlands. She and her colleagues used the mission's data to discover evidence of a major galactic merger that, some 10 billion years ago, shaped our home galaxy into the Milky Way we know today. 'With all that information, it was like a veil being lifted,' Helmi says. 'We could suddenly perform what's sometimes called 'galactic archaeology,' reconstructing the Milky Way's history to see when and how this merger happened with another, smaller galaxy that was about a third to a quarter of our galaxy's mass.... Gaia allows us to look billions of years into the Milky Way's history—before our solar system even formed—to see what actually happened back then, which is absolutely amazing.' Tracing perturbations from one more recent and ongoing merger, astronomers have even managed to reveal an apparent warp in the Milky Way's disk, offering a new twist—literally—on the classic image of our cosmic home. At smaller scales, the spacecraft has refined the orbits of more than 150,000 asteroids, surveilling hundreds of them to see if they have their own moons. It has spied hints of thousands of worlds and even a few black holes orbiting other stars. At larger scales, it has helped estimate the expansion rate of the universe, and it has also teased out the subtle tugging of the Milky Way's heart upon the solar system across tens of thousands of light-years. Gaia's sprawling cosmic reckoning is now a cornerstone for most state-of-the-art Earth- and space-based telescopes, which rely on the mission's target-dense celestial map to orient and calibrate their own observations and operations. Whether it's NASA's James Webb Space Telescope, ESA's Euclid mission, the ground-based, U.S.-built Vera C. Rubin Observatory or Europe's under-construction Extremely Large Telescope, practically all of the world's most exciting starlight-gathering telescopes will, in some sense, be guided by Gaia. And stunningly, the best is yet to come. More than two thirds of the mission's treasure trove of data is still under wraps. It is being prepared in a time-consuming process for two major upcoming milestones: about half of Gaia's total data are targeted for release next year, and the mission's full data are set to arrive no earlier than 2030. But because it didn't beam back images ready-made for lush wall posters and desktop backgrounds, Gaia was destined from the start to be 'criminally under-recognized outside astronomy,' says Mark McCaughrean, an astronomer and former senior adviser to ESA. 'And because Gaia provided utterly essential, if mundane, information such as precise stellar distances, it's been doomed with this curse of simultaneous ubiquity and obscurity as many people use its data but take it for granted as just 'coming from a catalog.'' Anthony Brown, an astronomer at Leiden University in the Netherlands, who leads the mission's data processing and analysis group, puts it most succinctly: 'For astronomers, Gaia has become almost like the air you breathe,' he says. At the heart of Gaia's mapmaking is a technique called astrometry, the measurement of celestial positions and motions in the plane of the sky. Paired with a phenomenon called parallax—the apparent shift of an object's position when viewed from two vantage points—astronomers can use Gaia for determining distances, too. You can see the parallax effect with your own two eyes: hold your thumb out at arm's length and watch as it appears to jump around as you blink one eye and then the other. The closer the object is, the bigger its displacement will be. And the bigger your baseline is between two vantage points, the smaller the displacement will be that you can discern. Your eyes have a baseline of about six centimeters; Gaia's was 300 million kilometers, set by the opposite sides of Earth's orbit around the sun. A Gaia predecessor, ESA's Hipparcos mission, used that same gigantic baseline to survey the sky from 1989 until it ran out of fuel in 1993. But the technology of the time limited Hipparcos's astrometric reckoning to a precision of about one milliarcsecond, with high-quality measurements only for about 100,000 objects within about 200 parsecs (650 light-years) of the solar system. (A single arc second is a very small angular slice of the heavens, making Hipparcos's milliarcsecond precision all the more noteworthy. The moon, for instance, takes up about 1,800 arc seconds in Earth's sky.) As impressive as Hipparcos was, Gaia shattered the records set by its precursor—although not without challenges, such as precision-threatening sprays of stray light that leaked around the edges of the spacecraft's sun shield and through a hole punched by an errant micrometeoroid. But ultimately, Brown says, Gaia's measurements achieved on the order of 100 times greater precision—reaching about 10 microarcseconds. And within the Milky Way, the spacecraft's view encompassed 100 times more volume and included 10 times more targets. The numbers underpinning Gaia are so alien to everyday experience that they border on nonsensical, says Michael Perryman, a former ESA researcher, who has served as project scientist for Hipparcos and Gaia and played a crucial developmental role for both missions. He likens Hipparcos's precision to discerning a second's worth of growth of a human hair from a distance of one meter. Gaia's 100-times-better view, he says, is more like measuring the width of a single hydrogen atom from the same distance. Another comparison involves the size of the two missions' datasets. When the Hipparcos team printed out its complete catalog, Perryman recalls, it comprised five thick volumes—almost enough to fill a single shelf of a bookcase. Printing out the full Gaia catalog with the same density of information per page, he says, would require about 10 kilometers of shelf space. 'The mind boggles,' he says. 'It's almost incomprehensible; these are numbers and dimensions we're simply not equipped to visualize, so even the analogies are very difficult to grasp.' The best example of the heights such precision can reach may be Gaia's tour de force determination of the solar system's acceleration with respect to a vast, sky-encompassing field of quasars. Quasars are the conspicuously bright cores of remote galaxies that harbor actively feeding supermassive black holes. As such, quasars are among the most powerful beacons astronomers can use to probe distant regions of the universe. Gaia pinpointed the positions of more than one and a half million of them to establish a fixed backdrop of sorts, against which various minuscule motions of our solar system or other nearby celestial objects could be seen. One motion Gaia managed to measure was an astonishingly small acceleration of just 0.232 nanometer per second squared—a continuous atom-scale deflection in the solar system's 220-kilometer-per-second trajectory through the Milky Way, attributed to the gravitational pull from our galaxy's center some 26,000 light-years away. Writ large, the displacement adds up to less than a meter per day—and essentially reflects the real-time sculpting of our galactic orbit as the solar system carves a path through the Milky Way's gravitational field. 'It's an almost circular motion around the galactic center, and it's directed toward the supermassive black hole there,' says astronomer Sergei Klioner of Germany's Dresden University of Technology, who led much of the work behind the measurement. 'No other observational data could come anywhere close to competing with Gaia here.... You often hear the term 'astronomical' in the sense of something being very large—but this is an example where Gaia has shown us something that's astronomically small.' Now that Gaia has gone dark, there's already talk of what comes next. 'Do we really need another astrometry mission?' asks Brown, who first began working on Gaia in 1997. 'Well, not immediately, but the extremely precise stellar reference frame it gave us—upon which many other observatories depend—will eventually deteriorate because all the stars are moving, right?' ESA is envisioning a follow-on mission, which would potential launching in the 2040s. This time that mission would be optimized for infrared observations to allow astronomers to see through the dust that otherwise clouds their view of the Milky Way's star-packed disk and galactic center. 'It's, in a way, wonderful but also a bit sad that people take Gaia for granted because, my God, it was a tough mission,' Perryman reflects. 'I don't feel sadness that it's gone; I'm just delighted and relieved it lasted so long, and I'm very conscious of how remarkable it is that we live in a time when society is willing to pool its resources to support such things, and we have the technology in place to do them. I hope this period continues—but I worry we've been taking that for granted, too.'
Yahoo
3 hours ago
- Yahoo
Alzheimer's and Parkinson's charities identify new ways to reuse current drugs
Scientists are to examine whether drugs that are already in use could be repurposed to treat the symptoms of both Alzheimer's disease and Parkinson's in a new collaboration which aims to discover novel treatments at pace. Experts say that by repurposing drugs, they can 'increase the shots on target' at tackling the diseases. This method of drug development could also reduce the time patients are left waiting for new treatments by up to 10 years, they added. It comes after the NHS spending watchdog rejected the use of new Alzheimer's drugs lecanemab and donanemab for widespread use in the health service. The drugs were approved for use in the UK last year by the UK's medicines regulator but the NHS spending watchdog, the National Institute for Health and Care Excellence (Nice), said they could not be used in the NHS because the benefits are 'too small' to justify the cost. Now charities Cure Parkinson's and Alzheimer's Research UK have joined forces to find current drugs that may tackle some of the common biology behind both diseases. After presentations to the International Linked Clinical Trials (iLCT), which was set up by Cure Parkinson's over a decade ago, experts from both fields will select the most promising drugs for both Parkinson's and dementia, so they can be moved quickly into clinical trials. Weight loss jabs are already being investigated for their effectiveness in treating symptoms of both diseases and experts hope to uncover more drugs that can have multiple uses. Semaglutide, the active ingredient for weight loss and diabetes drugs Wegovy and Ozempic, is being examined in clinical trials to see whether it can help patients with Alzheimer's disease or Parkinson's. Trial results for the Alzheimer's trial are expected to be published later this year. Dr Sheona Scales, director of research at Alzheimer's Research UK, told the PA news agency that the iLCT project had already been 'hugely successful' with people who have Parkinson's, adding: 'Around 30% of disease modifying therapies that are in clinical trials for Parkinson's disease came through this process. 'What we wanted to do is to build on their knowledge and experience and expertise in order to be able to bring a process similar to that to Alzheimer's disease.' Dr Scales said that there are some 'common grounds' between Parkinson's and Alzheimer's – both are neurodegenerative diseases and have some 'common biological processes' – such as inflammation, mitochondrial dysfunction and 'protein misfolding' – which could be targets for repurposed drugs. 'Getting multiple drugs that are targeting the disease is really important to us,' she said. 'Testing different types of drugs and getting as many shots on target is important.' She said: 'Repurposed drugs have already been demonstrated to be safe for use in humans development of new drugs for different diseases is a long process. 'What essentially bringing repurposed drugs does, is help to accelerate the drug development pipeline – it could save between five and 10 years within that process, compared to taking a new drug through clinical trials for the very first time.' Helen Matthews, chief executive of Cure Parkinson's, said the iLCT was originally set up to identify drugs that can potentially 'slow down, stop or reverse Parkinson's'. She added: 'It was through this programme that we realised that there were so many drugs that were also being looked at in the dementia field and there were commonalities there in terms of the drugs looking to reduce inflammation, or whatever it might be, there were specific pathways that those drugs were working on that could be beneficial for both disease areas. 'So given that we were already doing the (work) every year, it made sense to join forces in this way, just to add efficiencies. 'Because if you're looking at the same drugs, we'll only do that digging once, you know, only do that compilation of the dossiers once, so that you can actually take the learning for both diseases and then actually look and see which might be beneficial.' She said that the 'sharing of knowledge and digging' could also be shared with other disease areas, such as MS. And on lecanemab and donanemab, Dr Scales added: '(These) were the first disease-targeting therapies that have been licensed in the UK, but obviously are not available on the NHS at the moment. 'They showed for the very first time that we were able to alter the course of the disease. 'And what we're looking forward to now is what the next generation of treatments can bring us and how we can target different parts of the disease.' Dr Lucy Devendra, head of research at Alzheimer's Society, said: 'Repurposing medicines which are already known to be safe can help us find new treatments for the diseases that cause dementia much quicker. 'Although it is still early days, it's encouraging to see a renewed focus on this type of research and development.'
Yahoo
4 hours ago
- Yahoo
Archaeologists Were Exploring a Cave—and Found 100 Prehistoric Structures
Here's what you'll learn when you read this story: The discovery of more than 100 prehistoric structures in the Cova Dones cave in Spain makes it one of the most significant prehistoric underground sites in the world. Archaeologists found stalagmites intentionally reassembled within the caves, dating them to prehistoric times. Questions remain about the purpose of the underground structures in a cave already known for a wealth of finds. Prehistoric humans intentionally modified stalagmites in the Cova Dones cave in Spain, forming over 100 structures—known as speleofacts—as a result. The recent archaeological find becomes one of the most significant prehistoric underground discoveries in the world, according to the team behind the discovery. 'This finding shows the adaptation of the environment by the prehistoric communities and places the site as the second most important in the world in this category, only behind the French cave of Saint-Marcel,' the discovery team from the universities of Alicante and Zaragoza wrote in a translated statement. Located in Millares, Cova Dones may have just jumped to the forefront of prehistoric underground discussions, but answers may be hard to come by. The archaeological team identified more than 100 speleofacts coming from the fracture, displacement, or regrouping of stalagmites to form structures. Experts believe this is 'convincing evidence of the planned occupation of the underground environment by prehistoric societies.' Still, some of the patterning of the recreated forms leaves questions as to their purpose, whether ritual or instead related to site planning by forming boundaries. The team was able to start dating the speleofacts thanks to calcium regrowth on the fractures, allowing them to 'attribute, at least partially, these interventions to prehistoric periods.' The researchers plan to continue to study the speleofacts to better date the timing of the underground work and 'accurately determine the scope and chronology of these structures.' This isn't the first time the prehistoric nature of Cova Dones has surfaced. In 2023, Antiquity published a study classifying the cave as home to the largest set of Paleolithic rock art on the eastern Mediterranean coast of the Iberian Peninsula, with more than 100 paintings and engravings dated around 24,000 years old. The paintings included at least 19 animal representation in three different zones in the cave, some roughly 1,300 feet from the entrance. The study noted that all the zones were easily accessible without any climbing required. Key animals shown in the graphics included horses, deer, aurochs, and a stag. The researchers were able to date the cave art because of an overlap with cave bear claw marks and the artwork. Cave bears went extinct roughly 24,000 years ago. Shortly after the rock art finding, the existence of a 1,900-year-old Roman sanctuary was revealed in a room roughly 650 feet from the entrance of the cave, with a set of inscriptions and a coin of Emperor Claudius. The 2023 study noted that much of the cave system was yet unexplored by modern archaeologists, opening the possibility for additional finds. You Might Also Like The Do's and Don'ts of Using Painter's Tape The Best Portable BBQ Grills for Cooking Anywhere Can a Smart Watch Prolong Your Life?
